These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38078403)

  • 1. Discovery of novel cMET-targeting antibody Fab drug conjugates as potential treatment for solid tumors with highly expressed cMET.
    Lim RK; Buschman M; Khasanov A; Ledesma A; Chen J; Nguyen T; Guo J; Li L; Huang J; Niu J; Kerwin L; Wang R; Guo Y; Zhu T; Kaufmann G; Zhang Y; Zhou H; Ji H; Fu Y
    Expert Opin Biol Ther; 2023; 23(11):1137-1149. PubMed ID: 38078403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors.
    Gymnopoulos M; Betancourt O; Blot V; Fujita R; Galvan D; Lieuw V; Nguyen S; Snedden J; Stewart C; Villicana J; Wojciak J; Wong E; Pardo R; Patel N; D'Hooge F; Vijayakrishnan B; Barry C; Hartley JA; Howard PW; Newman R; Coronella J
    Mol Oncol; 2020 Jan; 14(1):54-68. PubMed ID: 31736230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
    Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
    BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
    BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models.
    Gavine PR; Ren Y; Han L; Lv J; Fan S; Zhang W; Xu W; Liu YJ; Zhang T; Fu H; Yu Y; Wang H; Xu S; Zhou F; Su X; Yin X; Xie L; Wang L; Qing W; Jiao L; Su W; Wang QM
    Mol Oncol; 2015 Jan; 9(1):323-33. PubMed ID: 25248999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma.
    Phan LM; Fuentes-Mattei E; Wu W; Velazquez-Torres G; Sircar K; Wood CG; Hai T; Jimenez C; Cote GJ; Ozsari L; Hofmann MC; Zheng S; Verhaak R; Pagliaro L; Cortez MA; Lee MH; Yeung SC; Habra MA
    Cancer Res; 2015 Oct; 75(19):4131-42. PubMed ID: 26282167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress of antibody-drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies.
    Mer AH; Mirzaei Y; Misamogooe F; Bagheri N; Bazyari A; Keshtkaran Z; Meyfour A; Shahedi A; Amirkhani Z; Jafari A; Barpour N; Jahandideh S; Rezaei B; Nikmanesh Y; Abdollahpour-Alitappeh M
    Drug Deliv Transl Res; 2024 Nov; 14(11):2963-2988. PubMed ID: 38597995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models.
    Yang CY; Wang L; Sun X; Tang M; Quan HT; Zhang LS; Lou LG; Gou SH
    Acta Pharmacol Sin; 2019 Jul; 40(7):971-979. PubMed ID: 30643210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High antitumor activity of Sortase A-generated anti-CD20 antibody fragment drug conjugates.
    Liu W; Zhao W; Bai X; Jin S; Li Y; Qiu C; Pan L; Ding D; Xu Y; Zhou Z; Chen S
    Eur J Pharm Sci; 2019 Jun; 134():81-92. PubMed ID: 30986472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer.
    Lu J; Li G; He K; Jiang W; Xu C; Li Z; Wang H; Wang W; Wang H; Teng X; Teng L
    J Transl Med; 2015 Feb; 13():42. PubMed ID: 25638174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-canonical cMet regulation by vimentin mediates Plk1 inhibitor-induced apoptosis.
    Singh R; Peng S; Viswanath P; Sambandam V; Shen L; Rao X; Fang B; Wang J; Johnson FM
    EMBO Mol Med; 2019 May; 11(5):. PubMed ID: 31040125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met.
    Tong M; Gao M; Xu Y; Fu L; Li Y; Bao X; Fu H; Quan H; Lou L
    Cancer Sci; 2019 Nov; 110(11):3584-3594. PubMed ID: 31446643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the hepatocyte growth factor-cMET axis in cancer therapy.
    Blumenschein GR; Mills GB; Gonzalez-Angulo AM
    J Clin Oncol; 2012 Sep; 30(26):3287-96. PubMed ID: 22869872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer.
    Moran-Jones K
    Mol Diagn Ther; 2016 Jun; 20(3):199-212. PubMed ID: 27139908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma.
    Moschetta M; Basile A; Ferrucci A; Frassanito MA; Rao L; Ria R; Solimando AG; Giuliani N; Boccarelli A; Fumarola F; Coluccia M; Rossini B; Ruggieri S; Nico B; Maiorano E; Ribatti D; Roccaro AM; Vacca A
    Clin Cancer Res; 2013 Aug; 19(16):4371-82. PubMed ID: 23804425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
    Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
    Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance.
    Hamann PR; Hinman LM; Beyer CF; Greenberger LM; Lin C; Lindh D; Menendez AT; Wallace R; Durr FE; Upeslacis J
    Bioconjug Chem; 2005; 16(2):346-53. PubMed ID: 15769088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms.
    Matte I; Lane D; Laplante C; Garde-Granger P; Rancourt C; Piché A
    Int J Cancer; 2015 Jul; 137(2):289-98. PubMed ID: 25482018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site-Specific Antibody-Drug Conjugates in Triple Variable Domain Fab Format.
    Hwang D; Rader C
    Biomolecules; 2020 May; 10(5):. PubMed ID: 32422893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interplay between VEGF-A and cMET signaling in human vestibular schwannomas and schwann cells.
    Dilwali S; Roberts D; Stankovic KM
    Cancer Biol Ther; 2015; 16(1):170-5. PubMed ID: 25692621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.